NasdaqGS:BEAMBiotechs
Assessing Beam Therapeutics (BEAM) Valuation After Positive AATD Regulatory Update
Beam Therapeutics (BEAM) is back in focus after a favorable regulatory update for its Alpha-1 Antitrypsin Deficiency program, a key development that analysts view as important for the company’s near term pipeline plans.
See our latest analysis for Beam Therapeutics.
Despite the positive attention from the Alpha-1 Antitrypsin Deficiency update, Beam Therapeutics’ 1-day share price return of 5.7% and 7-day return of 12.48% are both negative, while its 90-day share price return of 10.44%...